November 14, 2011
Vanderbilt University has signed up 70 HIV-negative men who have sex with men for its part in a national HIV vaccine trial and now is looking to enroll more. Researchers have boosted their nationwide enrollment goal for the HVTN 505 trial from 1,350 to 2,200. The trial was conceived to study whether the vaccine could lower viral load in those infected; the expansion reflects scientists' desire to determine whether the vaccine can significantly reduce the number of new infections. For more information on how to volunteer, telephone 615-322-HOPE (4673) or visit www.HopeTakesAction.org.
Adapted from:
The Tennessean (Nashville)
10.19.2011; Tom Wilemon

This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
|
No comments have been made.
|
|
|